ANCA glomerulonephritis is a serious kidney disease in which the body’s own immune system attacks the tiny blood vessels inside the kidneys, causing rapid inflammation and loss of function. It is driven by antibodies called ANCAs (anti-neutrophil cytoplasmic antibodies), which target proteins on white blood cells and trigger them to damage small blood vessels. Without prompt treatment, the condition can destroy kidney tissue within weeks to months. The good news is that modern immunosuppressive therapies have dramatically improved outcomes, though treatment itself carries real risks that need careful management.
What Happens Inside the Kidneys
The kidneys filter blood through millions of tiny structures called glomeruli. In ANCA glomerulonephritis, the immune system produces antibodies that latch onto one of two proteins found on neutrophils (a type of white blood cell): myeloperoxidase (MPO) or proteinase 3 (PR3). When these antibodies bind to primed neutrophils, the white blood cells become overactivated and begin damaging the walls of small blood vessels in the glomeruli.1PubMed Central. ANCA Glomerulonephritis and Vasculitis
A key amplification step involves the complement system, a part of innate immunity. When ANCA-activated neutrophils release their contents, they set off complement activation through the so-called alternative pathway. This generates a molecule called C5a, which in turn primes even more neutrophils, creating a self-reinforcing cycle of inflammation.2PubMed Central. The rise of complement in ANCA‐associated vasculitis: from marginal player to target of modern therapy Animal studies have shown that blocking the C5a receptor on neutrophils can nearly abolish disease development, which is why this receptor became an important drug target.3PubMed Central. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis
Genetic variation in complement components also matters. Certain inherited variants in the alternative complement pathway are associated with who gets the disease in the first place and how badly the kidneys are affected. People with higher baseline activity of this pathway and certain plasma protein ratios tend to have more severe kidney involvement.4PubMed. Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Under the microscope, the damage has a distinctive look. Kidney biopsies typically show areas where the glomerular walls have broken apart, with patches of dead tissue and crescent-shaped collections of cells crowding into the filtering space. A hallmark of the condition is that immunofluorescence staining shows little or no antibody deposition on the tissue, which is why pathologists call it “pauci-immune” (meaning “few immune deposits”) glomerulonephritis.5American Journal of Kidney Diseases. AJKD Atlas of Renal Pathology: Pauci-immune Necrotizing Crescentic Glomerulonephritis This pauci-immune pattern is the single most common cause of rapidly progressive glomerulonephritis.6PubMed Central. Pauci-Immune Crescentic Glomerulonephritis: An ANCA-Associated Vasculitis
Recognizing the Symptoms
ANCA glomerulonephritis rarely announces itself with a single unmistakable symptom. Many people first notice vague signs: fatigue, unintentional weight loss, joint aches, or low-grade fevers. These nonspecific complaints can drag on for weeks before kidney involvement becomes obvious, which is one reason diagnosis is often delayed.
When the kidneys are actively affected, the most consistent finding is blood in the urine. In one study of patients with ANCA-associated glomerulonephritis, every single patient had hematuria at baseline, and about 95% also had protein spilling into the urine.7PubMed Central. Hematuria duration does not predict kidney function at 1 year in ANCA-associated glomerulonephritis Some of this blood is visible (dark, tea-colored, or frankly red urine), but in many cases it is only detected on a lab dip test.
Kidney function can decline fast. In a series of patients presenting with acute kidney injury from ANCA-associated vasculitis, the majority arrived already at an advanced stage of kidney failure, with several needing dialysis at admission.8Nephrology Dialysis Transplantation. Acute kidney in patients with ANCA associated vasculitis This rapid trajectory is what makes early recognition so critical.
Because ANCA vasculitis is a systemic disease, kidney symptoms rarely exist in isolation. Depending on the subtype, people may also develop:
- Lung involvement: cough, shortness of breath, or coughing up blood (pulmonary hemorrhage), which can be life-threatening if unrecognized.
- Upper airway disease: chronic sinusitis, nosebleeds, or a saddle-nose deformity from cartilage damage (especially in granulomatosis with polyangiitis).
- Skin changes: a purplish rash on the legs, small ulcers, or tender nodules.
- Nerve damage: numbness, tingling, or weakness in the hands or feet from inflammation of small nerve-supplying vessels.
How It Is Diagnosed
Diagnosis rests on three pillars: blood tests for ANCA, urine analysis, and kidney biopsy. No single test is sufficient on its own.
ANCA Blood Testing
The blood test looks for antibodies against PR3 or MPO. A large meta-analysis found that modern antigen-specific immunoassays for PR3-ANCA have a sensitivity in the range of about 80–87% and a specificity above 96%.9PubMed. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis Testing for MPO-ANCA is somewhat less sensitive (around 58% across all assay methods) but still highly specific. These numbers have practical implications: a positive result in someone with compatible symptoms is very strong evidence, but a negative ANCA test does not rule the disease out. Roughly 10–15% of patients with the classic biopsy pattern test ANCA-negative.
International consensus now supports going straight to antigen-specific immunoassay testing for PR3 and MPO rather than starting with the older indirect immunofluorescence screening method, because the newer tests perform as well or better overall.9PubMed. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis
Kidney Biopsy and Scoring
A biopsy remains the gold standard for confirming the diagnosis and gauging how much damage has already occurred. The tissue sample tells the clinician how many glomeruli are actively inflamed versus scarred beyond repair, which directly informs treatment decisions and prognosis.
A scoring system known as the ANCA Renal Risk Score (ARRS) uses biopsy findings alongside clinical data to predict who is most likely to progress to end-stage kidney disease. Validated in a national cohort, higher ARRS categories were strongly associated with worse kidney outcomes, and the score predicted the need for dialysis better than kidney function measurements or protein levels in the urine alone.10Kidney International Reports. Validation of the ANCA Renal Risk Score in a National Cohort A prospective comparison of two scoring methods found the Renal Risk Score had the edge for predicting long-term outcomes.11PubMed Central. The prognostic value of two histopathologic classification models of ANCA-associated glomerulonephritis: a prospective study In practical terms, a biopsy that shows mostly fresh crescents and little scarring signals recoverable disease; one dominated by fibrous scarring suggests that aggressive immunosuppression is less likely to restore function.
Induction Treatment
Treatment is divided into two phases. The first, induction, aims to shut down the active inflammation as quickly as possible. The second, maintenance, keeps the disease in remission long-term.
Rituximab and Cyclophosphamide
The two main induction options are rituximab (a drug that depletes B cells, which produce the harmful antibodies) and cyclophosphamide (a broad immunosuppressant). The landmark RAVE trial showed that rituximab was at least as effective as cyclophosphamide for inducing remission overall and was significantly better in people whose disease had relapsed. About two-thirds of patients in the rituximab group achieved remission compared with roughly half in the cyclophosphamide group.12PubMed Central. Rituximab versus cyclophosphamide for ANCA-associated vasculitis Rituximab was also effective in patients with major kidney involvement or lung hemorrhage.
A later observational study looking specifically at granulomatosis with polyangiitis (one of the ANCA vasculitis subtypes) found an even larger advantage for rituximab, with about 73% of rituximab-treated patients reaching remission versus roughly 40% of those given cyclophosphamide.13JAMA Network Open. Rituximab vs Cyclophosphamide Induction Therapy for Patients With Granulomatosis With Polyangiitis Rituximab has increasingly become the first-line choice for most patients, though cyclophosphamide remains an option when rituximab is unavailable or in specific clinical scenarios.
Reducing Steroid Dependence With Avacopan
Both induction regimens have traditionally been paired with high-dose glucocorticoids (steroids) to rapidly suppress inflammation. While effective, long-term steroids carry well-known side effects: weight gain, diabetes, bone thinning, mood changes, and increased infection risk. Avacopan, a pill that blocks the C5a receptor (the same receptor shown to be critical in animal models of the disease), was developed specifically to reduce or replace steroids in ANCA vasculitis treatment. Clinical trials demonstrated that avacopan could significantly lower the cumulative steroid dose patients needed.14PubMed Central. Evaluating Avacopan in the Treatment of ANCA-Associated Vasculitis: Design, Development and Positioning of Therapy It is now recommended in international guidelines as a steroid-sparing agent in ANCA vasculitis management.15PubMed Central. Avacopan as a Steroid-Sparing Therapy in Relapsing Granulomatosis With Polyangiitis
Plasma Exchange
Plasma exchange physically removes circulating ANCA and inflammatory mediators from the blood. For decades, available data suggested it reduced the risk of progressing to end-stage kidney disease by roughly 40% in patients presenting with severe kidney involvement.16PubMed. Role of therapeutic plasmapheresis in ANCA-associated vasculitis However, the large PEXIVAS trial challenged this conclusion, finding that adding plasma exchange to standard immunosuppression did not significantly reduce the rate of death or end-stage kidney disease.17Kidney and Dialysis. Should We Still Use Therapeutic Plasma Exchange for Rapidly Progressive Glomerulonephritis in ANCA Associated Vasculitis? As a result, plasma exchange is no longer routinely recommended for all patients. It may still be considered in very severe presentations, such as life-threatening lung hemorrhage or kidney failure requiring dialysis, but the evidence supporting it is weaker than once believed.
Staying in Remission
Achieving remission is only half the battle. ANCA vasculitis relapses frequently, especially in people with PR3-ANCA or those who had respiratory involvement at diagnosis.18PubMed. Risk of Relapse of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in a Randomized Controlled Trial of Plasma Exchange and Glucocorticoids Maintenance therapy aims to keep the immune system in check without the toxicity of full induction regimens.
Rituximab has proven significantly more effective than the older standard of azathioprine for preventing relapses. In one randomized trial, only about 5% of patients on rituximab maintenance had a major relapse by 28 months, compared with 29% on azathioprine.19PubMed. Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis A later international trial in patients with relapsing disease confirmed the advantage, with rituximab cutting the risk of relapse by roughly 60% compared with azathioprine, without increasing the rate of serious side effects.20PubMed Central. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
The optimal duration of maintenance therapy is still debated. Many specialists continue rituximab infusions every four to six months for at least two years, though some patients with persistent PR3-ANCA positivity or a history of multiple relapses may need longer treatment. Stopping too early is one of the most common triggers for disease flares.
Treatment Complications
Immunosuppressive therapy is lifesaving but it comes with real costs. The most dangerous complication is infection. In the first year of treatment, infection rather than uncontrolled vasculitis itself is the leading cause of death.21PubMed. Complications of therapy for ANCA-associated vasculitis The suppressed immune system leaves patients vulnerable to bacteria, viruses, and opportunistic organisms that would not normally cause problems. Pneumocystis pneumonia is a particular concern; prophylactic antibiotics are routinely prescribed during intense immunosuppression. Annual flu and pneumococcal vaccinations are also recommended, along with screening for tuberculosis and hepatitis B before starting treatment.22PubMed Central. Avoidance of Harm From Treatment for ANCA-Associated Vasculitis
Cyclophosphamide, when used, carries additional risks including bladder toxicity and a dose-dependent increase in cancer risk (especially bladder cancer) with cumulative exposure, which is one more reason rituximab has become preferred for many patients. Rituximab can cause low immunoglobulin levels over time, potentially increasing late infections. Regular monitoring of immunoglobulin levels is standard practice during prolonged rituximab use.
Long-Term Kidney Outcomes
Even with modern treatment, ANCA glomerulonephritis takes a meaningful toll on long-term kidney function. In a large long-term follow-up study, about 17% of patients had progressed to end-stage kidney disease at five years and roughly 22% at ten years.23PubMed Central. Long-term outcome of kidney function in patients with ANCA-associated vasculitis Those who reached end-stage kidney disease had nearly three times the risk of dying compared with those whose kidney function was preserved. The degree of scarring on the initial biopsy and how much kidney function had already been lost at diagnosis are the strongest predictors of whether a person will need dialysis down the road.
For patients who do progress to end-stage kidney disease, kidney transplantation is possible, but it carries a higher relapse rate than seen in patients maintained on their native kidneys.24PubMed Central. Outcomes of Renal Transplantation in ANCA-Associated Vasculitis: A Systematic Review and Meta-Analysis Most transplant programs require the disease to be in sustained remission, typically for at least six to twelve months, before listing a patient. Recurrence in the graft does occur but graft survival overall remains reasonable compared with other causes of kidney failure.
Patients who are ANCA-negative at diagnosis (those with the classic biopsy pattern but no detectable ANCA in the blood) may have a somewhat faster early decline in kidney function, though long-term survival does not clearly differ from ANCA-positive patients in adjusted analyses.25PubMed Central. Long-term Prognosis of Anti-Neutrophil Cytoplasmic Antibody-Negative Renal Vasculitis: Cohort Study in Korea
Monitoring for Relapse
Detecting a relapse early, before significant kidney damage accumulates, is one of the biggest practical challenges. Standard monitoring relies on serial ANCA levels, kidney function blood tests, and urine testing for blood and protein. Rising ANCA titers can signal trouble, but they are an imperfect early-warning system: some patients relapse without a noticeable rise, and others have persistently elevated titers without flaring.
A promising newer biomarker is urinary soluble CD163 (usCD163), a molecule shed by activated immune cells in inflamed kidney tissue. Multiple studies have shown that usCD163 tracks closely with active kidney vasculitis. One study found it had a sensitivity of 94% and specificity of 91% for detecting relapse in biopsy-proven ANCA-associated glomerulonephritis, outperforming routine clinical measures like creatinine or urinary protein levels.26PubMed Central. Urinary Soluble CD163 and Disease Activity in Biopsy-Proven ANCA-Associated Glomerulonephritis A diagnostic cutoff has been proposed, with values above a certain threshold accurately distinguishing true vasculitis flares from other causes of acute kidney injury that can mimic relapse.27PubMed Central. The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis The test is not yet part of routine clinical practice everywhere, but it is gaining traction and could eventually reduce the need for repeat biopsies to confirm relapse.
Environmental Triggers
What actually causes the immune system to start producing ANCAs in the first place is not fully understood, but a few environmental exposures have been studied. Silica dust, encountered in occupations like mining, sandblasting, and construction, has drawn the most attention. Long-term silica exposure appears to contribute to ANCA production, though exposure alone without the lung scarring typical of silicosis was not associated with ANCA positivity in one study.28PubMed. Exposure to silica and risk of ANCA-associated vasculitis Certain drugs can also trigger the disease. Propylthiouracil, a medication used for overactive thyroid, is the best-documented culprit, with reported cases ranging from mild rashes to severe kidney and lung involvement.29Pediatrics. Occult Pulmonary Hemorrhage as a Rare Presentation of Propylthiouracil-Induced Vasculitis Other drugs implicated in rare cases include hydralazine and levamisole-contaminated cocaine. Infections, particularly those in the upper respiratory tract, are sometimes reported as preceding a flare, though a direct causal link is hard to establish.
Fatigue and Quality of Life
One of the most underappreciated aspects of living with ANCA vasculitis is persistent fatigue. In a quality-of-life study of ANCA vasculitis patients, fatigue emerged as the single biggest contributor to impaired well-being. What made this finding surprising was that objective disease markers failed to explain it: inflammation levels, kidney function, disease duration, damage scores, and prior treatment type all showed no significant association with how tired patients felt.30PubMed Central. Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis In other words, patients in remission with normal lab work often felt just as exhausted as those with active disease.
This disconnect between lab results and lived experience is frustrating for patients and clinicians alike. Fatigue in autoimmune conditions is likely driven by a combination of immune dysregulation, disrupted sleep, medication side effects, deconditioning, and psychological factors like anxiety about relapse. It does not respond reliably to treating the underlying vasculitis alone, which means it needs to be addressed as its own problem rather than expected to resolve once kidney numbers improve. Exercise programs, sleep hygiene, and psychological support are increasingly recognized as essential parts of managing ANCA vasculitis, not just add-ons to immunosuppression.